Molecular Genetics of Melanoma

黑色素瘤的分子遗传学

基本信息

批准号：
9070614
负责人：
HENSIN TSAO
金额：
$ 17.2万
依托单位：
MASSACHUSETTS GENERAL HOSPITAL
依托单位国家：
美国
项目类别：
财政年份：
2010
资助国家：
美国
起止时间：
2010-05-01 至 2020-04-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9070614
关键词：
Area Award Cancer Center Candidate Disease Gene Clinical Clinical Research Clinical Trials Collaborations Complex Analysis Computational Biology Cutaneous Melanoma Dermatology Dose Educational Curriculum Elements Environment Family Funding Genetic Genetic Programming Genomic medicine Goals Grant Health Human Individual Institutes Interdisciplinary Study International Investigation Investments Laboratories Lesion Life Cycle Stages MAP Kinase Gene MDM2 gene Malignant Neoplasms Manuscripts Massive Parallel Sequencing Medical Medical Oncology Medical Students Mentors Mentorship Metastatic Melanoma Mid-Career Clinical Scientist Award (K24)Modeling Molecular Molecular Analysis Molecular Genetics Mutation Ocular Melanoma Patient risk Patients Peer Review Grants Pigments Postdoctoral Fellow Predisposition Publishing Recruitment Activity Research Research Infrastructure Research Personnel Risk Role Sampling Science Scientist Staging Structure Susceptibility Gene TP53 gene Technology Therapeutic Time Training Visit apprenticeship base career clinical material exome sequencing experience graduate medical education improved in vivo Model interest investigator training melanoma multidisciplinary next generation sequencing novel novel strategies patient oriented patient oriented research pre-clinical precision medicine predictive modeling programs sound targeted treatment therapy resistant translational genetics tumor growth

Area Award Cancer Center Candidate Disease Gene Clinical Clinical Research Clinical Trials Collaborations Complex Analysis Computational Biology Cutaneous Melanoma Dermatology Dose Educational Curriculum Elements Environment Family Funding Genetic Genetic Programming Genomic medicine Goals Grant Health Human Individual Institutes Interdisciplinary Study International Investigation Investments Laboratories Lesion Life Cycle Stages MAP Kinase Gene MDM2 gene Malignant Neoplasms Manuscripts Massive Parallel Sequencing Medical Medical Oncology Medical Students Mentors Mentorship Metastatic Melanoma Mid-Career Clinical Scientist Award (K24)Modeling Molecular Molecular Analysis Molecular Genetics Mutation Ocular Melanoma Patient risk Patients Peer Review Grants Pigments Postdoctoral Fellow Predisposition Publishing Recruitment Activity Research Research Infrastructure Research Personnel Risk Role Sampling Science Scientist Staging Structure Susceptibility Gene TP53 gene Technology Therapeutic Time Training Visit apprenticeship base career clinical material exome sequencing experience graduate medical education improved in vivo Model interest investigator training melanoma multidisciplinary next generation sequencing novel novel strategies patient oriented patient oriented research pre-clinical precision medicine predictive modeling programs sound targeted treatment therapy resistant translational genetics tumor growth

展开

项目摘要

DESCRIPTION (provided by applicant): This K24 renewal application for Molecular Genetics of Melanoma is an expansion of the candidate's previous K24 grant with greater scientific and mentorship investment in patient risk prediction through Next Generation sequencing and in the rapidly growing area of molecular therapeutics. The first five years of this K24 was instrumental in providing the candidate protected time to train investigators in patient-oriented research. The results of his research led to the first Bayes-Mendel risk prediction model in melanoma (MelaPRO) and the description of novel MITF and BAP1 mutations in melanoma-prone families. The candidate was able to mentor 19 individuals, publish 52 manuscripts and successfully compete for over $2.8 million in peer-reviewed grants. Since the initial K24 award in 2010, massive parallel sequencing technologies have become commonplace and genomic medicine is being deployed at the patient's bedside. This K24 renewal proposes to exploit the power of precision medicine to more comprehensively profile melanoma risk and to capitalize on newly-discovered molecular drivers to improve melanoma therapeutics. The scientific expansion builds upon the candidate's long-time experience with patient- oriented genetics investigation and affords him the opportunity to mentor trainees in new areas of interdisciplinary research. The tightly-woven multidisciplinary collaborations which already exist between the candidate and investigators at the MGH Analytic Translational Genetics Unit/Broad Institute and the MGH Cancer Center/Henri and Belinda Termeer Center for Targeted Therapies will allow for (i) new opportunities to mentor and recruit trainees in unrelated fields into patient-oriented research, (i) access to patients and patient-derived material for analysis, (iii) well-defined infrastructures to carry out the proposed studies and (iv) new areas of funding not currently in the candidate's portfolio. This award will also enable the candidate to develop new areas of expertise, to codify new approaches to mentorship and to take on new directions in patient-oriented research.

描述（由应用提供）：这种K24黑色素瘤分子遗传学的更新应用是候选人以前的K24赠款的扩展，并通过下一代测序以及分子治疗的快速增长领域对患者风险预测进行了更大的科学和心态投资。这款K24的前五年有助于为候选人提供受患者研究的研究人员的培训时间。他的研究结果导致黑色素瘤（Melapro）中的第一个贝叶斯 - 孟德尔风险预测模型以及易黑色素瘤家族中新型MITF和BAP1突变的描述。候选人能够为19个人进行精神上的精神，出版52份手稿，并成功竞争超过280万美元的同行评审赠款。自2010年首次获得K24奖以来，大规模的平行测序技术已变得司空见惯，并且正在在患者的床边部署基因组医学。这项K24更新提案旨在探索精确医学的力量，以更全面地介绍黑色素瘤风险，并利用新发现的分子驱动因素来改善黑色素瘤疗法。科学的扩展是基于候选人在以患者为导向的遗传学投资的长期经验的基础上，为他提供了在跨学科研究的新领域的精神学员的机会。 MGH分析转化遗传学单位/大研究所和MGH癌症中心/Henri和Belinda Termeer靶向疗法中已经存在的紧密编织的多学科合作，该候选者与研究人员之间已经存在，该遗传学单位/广泛研究所和贝琳达癌症中心将有（i）（i）（i）对患者和患者（II）对患者进行分析（I）的良好招聘人员的新机会基础架构进行拟议的研究和（iv）候选人投资组合中目前尚未进行新的资金领域。该奖项还将使候选人能够开发新的专业知识领域，将新的心态方法编纂并在以患者为导向的研究中探讨新的方向。